文献速递慢阻肺呼吸道感染

NTHi-Mcat疫苗预防慢阻肺急性加重的2b期试验

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
PubMed 文献 · Lancet Respir Med · 2022-01-10

这项多中心、随机、安慰剂对照、观察者盲法、概念验证2b期试验在606例稳定期慢阻肺患者中评估NTHi-Mcat疫苗的疗效与安全性。

要点

  • NTHi-Mcat疫苗未降低慢阻肺中重度急性加重年发生率。
  • 疫苗组局部不良事件更常见(72% vs 11%),一般不良事件两组相似。
  • 未发现与疫苗相关的安全性问题。

核心结论

  • NTHi-Mcat疫苗未能减少慢阻肺中重度急性加重的年发生率,但未发现安全性问题。

研究设计与样本

  • 多中心、随机、观察者盲法、安慰剂对照、概念验证2b期试验,在比利时、加拿大、法国、德国、意大利、西班牙、英国和美国67个临床中心招募40-80岁、GOLD 2-4级、前一年至少一次中重度急性加重的稳定期慢阻肺患者。
  • 606例入选总疫苗队列(疫苗组304例,安慰剂组302例),571例接受两剂并纳入主要疗效分析(疫苗组279例,安慰剂组292例)。

主要发现

  • 征集性局部不良事件疫苗组216/301例(72%)高于安慰剂组34/299例(11%),征集性全身不良事件两组相似(239/301例[79%] vs 235/299例[79%])。
  • 疫苗组1例死亡(急性呼吸衰竭,与接种无关),安慰剂组10例死亡(其中7例部分归因于慢阻肺或呼吸衰竭)。
  • 疫苗组严重不良事件158例次(89/304例[29%],与接种无关),安慰剂组214例次(99/302例[33%])。

临床怎么用

  • 不推荐使用NTHi-Mcat疫苗预防慢阻肺中重度急性加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with changes in the sputum microbiome, including an increased prevalence of pathogenic bacteria. Vaccination against the most frequent bacteria identified in AECOPD might reduce exacerbation frequency. We assessed the efficacy, safety, and immunogenicity of a candidate vaccine containing surface proteins from non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) in patients with COPD. METHODS: This multicentre, randomised, observer-blinded, placebo-controlled, proof-of-concept, phase 2b trial recruited patients with stable COPD, moderate-to-very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 2, 3, or 4), at 67 clinical sites in Belgium, Canada, France, Germany, Italy, Spain, UK, and USA. Eligible patients were aged 40-80 years and had a history of at least one moderate or severe exacerbation in the previous year. Patients were allocated (1:1) using a minimisation algorithm to receive two intramuscular injections of NTHi-Mcat vaccine or placebo 60 days apart, in addition to standard care. The allocation algorithm considered age category, number of previous exacerbations, COPD severity at study entry, and country as minimisation factors, to guarantee treatment balance within each factor. Vaccine recipients and those responsible for evaluating study endpoints were masked to group allocation. In the analysis of efficacy, the primary outcome was the rate of any moderate or severe AECOPD occurring within a 1-year period, starting 1 month after the second dose in patients who received two vaccine doses (modified total vaccinated cohort). Safety was assessed in the total vaccinated cohort. The trial is registered with ClinicalTrials.gov, number NCT03281876, and is complete. FINDINGS: Between Nov 27, 2017, and Nov 30, 2018, 606 adults were enrolled and included in the total vaccinated cohort (304 in the NTHi-Mcat vaccine group, 302 in the placebo group); 571 received two doses and were included in the primary efficacy analysis (279 in the NTHi-Mcat vaccine group, 292 in the placebo group). 23 participants dropped-out in the NTHi-Mcat vaccine group and 39 in the placebo group; this included 4 patients in the NTHi-Mcat vaccine group and 15 in the placebo group who withdrew from the study because of an adverse event. The primary analysis included 340 exacerbations (in follow-up time 102 123 days) in the NTHi-Mcat vaccine group and 333 (in 104 443 days) in the placebo group, with a yearly rate of moderate or severe AECOPD of 1·22 in the NTHi-Mcat vaccine group and 1·17 in the placebo group, with vaccine efficacy in reducing the yearly rate of moderate or severe AECOPD estimated to be zero (vaccine efficacy point estimate 2·26% [87% CI -18·27 to 11·58]; p=0·82). Solicited local adverse events were more frequent in the NTHi-Mcat vaccine group (216 [72%] of 301 patients) than with placebo (34 [11%] of 299 patients), and the frequency of solicited general adverse events was similar between groups (239 [79%] of 301 vs 235 [79%] of 299 patients). There was one death in the NTHi-Mcat vaccine group (acute respiratory failure, not related to vaccination) and ten in the placebo group (seven due in part to COPD or respiratory failure). There were 158 serious adverse events (89 [29%] of 304 patients) in the NTHi-Mcat vaccine group, not related to vaccination, and 214 (99 [33%] of 302 patients) in the placebo group. INTERPRETATION: NTHi-Mcat vaccine administered to patients with COPD did not show efficacy in reducing the yearly rate of moderate or severe exacerbations. No safety concerns were identified. FUNDING: GlaxoSmithKline Biologicals SA.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Andreas, Testa, Boyer, et al. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respir Med. 2022. PMID: 35026180. doi:10.1016/S2213-2600(21)00502-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。